Page 138 - 《中国药房》2023年9期
P. 138

to  simvastatin  treatment[J].  J  Cardiovasc  Pharmacol,  genet Genomics,2017,27(8):285-293.
               2020,75(2):168-173.                            [36]  ZHANG L H,KAMANNA V S,GANJI S H,et al. Niacin
          [24]  SAŁACKA A,BOROŃ A,GORĄCY I,et al. An associa‐      increases  HDL  biogenesis  by  enhancing  DR4-dependent
               tion  of  ABCG8:rs11887534  polymorphism  and  HDL-  transcription  of ABCA1  and  lipidation  of  apolipoprotein
               cholesterol response to statin treatment in the Polish popu‐  A-I in HepG2 cells[J]. J Lipid Res,2012,53(5):941-950.
               lation[J]. Pharmacol Rep,2021,73(6):1781-1786.  [37]  HU M,CHU W C,YAMASHITA S,et al. Liver fat reduc‐
          [25]  LIU M Y,FAN F F,ZHANG Y,et al. The association of   tion with niacin is influenced by DGAT-2 polymorphisms
               GATM  polymorphism  with  statin-induced  myopathy:a   in hypertriglyceridemic patients[J]. J Lipid Res,2012,53
               systematic review and meta-analysis[J]. Eur J Clin Phar‐  (4):802-809.
               macol,2021,77(3):349-357.                      [38]  HU M,YANG Y L,NG C F,et al. Effects of phenotypic
          [26]  CHAPMAN  M  J.  Fibrates  in  2003:therapeutic  action        and  genotypic  factors  on  the  lipid  responses  to  niacin  in
               in  atherogenic  dyslipidaemia  and  future  perspectives[J].   Chinese  patients  with  dyslipidemia[J].  Medicine (Balti‐
               Atherosclerosis,2003,171(1):1-13.                   more),2015,94(20):e881.
          [27]  HOUSE J S,MOTSINGER-REIF A A. Fibrate pharmaco-   [39]  BAE  J  W,CHOI  C  I,LEE  J  H,et  al.  Effects  of  UDP-
               genomics:expanding  past  the  genome[J].  Pharmacoge‐  glucuronosyltransferase polymorphisms on the pharmaco‐
               nomics,2020,21(4):293-306.                          kinetics  of  ezetimibe  in  healthy  subjects[J].  Eur  J  Clin
          [28]  LIU Y  J,ORDOVAS  J  M,GAO  G  M,et  al.  Pharmaco-    Pharmacol,2011,67(1):39-45.
               genetic association of the APOA1/C3/A4/A5 gene cluster   [40]  ALTMANN  S  W,DAVIS  H  R  Jr,ZHU  L  J,et  al.
               and  lipid  responses  to  fenofibrate:the  genetics  of  lipid-  Niemann-Pick  C1  Like  1  protein  is  critical  for  intestinal
               lowering drugs and diet network study[J]. Pharmacogenet   cholesterol  absorption[J].  Science,2004,303(5661):
               Genomics,2009,19(2):161-169.                        1201-1204.
          [29]  WOJCZYNSKI  M  K,GAO  G  M,BORECKI  I,et  al.     [41]  LOU  X  Y,QIN  C  Z,BAO  M  H,et  al.  Analysis  of
               Apolipoprotein B genetic variants modify the response to   Niemann-Pick  C1-like  1 (NPC1L1)  genetic  polymor‐
               fenofibrate:a  GOLDN  study[J].  J  Lipid  Res,2010,51  phisms  and  haplotypes  in  Chinese  Han  population[J].
              (11):3316-3323.                                      Pharmazie,2015,70(9):581-585.
          [30]  TSAI M Y,ORDOVAS J M,LI N,et al. Effect of fenofi‐  [42]  ZSÍROS N,BODOR M,VARGA V,et al. The c.-133A >
               brate therapy and ABCA1 polymorphisms on high-density   G polymorphism in NPC1L1 gene influences the efficacy
               lipoprotein subclasses in the Genetics of Lipid Lowering   of ezetimibe monotherapy on apolipoprotein A1 in hyper‐
               Drugs and Diet Network[J]. Mol Genet Metab,2010,100  lipidemic patients[J]. Pharmazie,2014,69(6):424-429.
              (2):118-122.                                    [43]  PISCIOTTA L,FASANO T,BELLOCCHIO A,et al. Ef‐
          [31]  LIU Y J,ORDOVAS J M,GAO G M,et al. The SCARB1      fect of ezetimibe coadministered with statins in genotype-
               gene  is  associated  with  lipid  response  to  dietary  and      confirmed  heterozygous  FH  patients[J].  Atherosclerosis,
               pharmacological interventions[J]. J Hum Genet,2008,53  2007,194(2):e116-e122.
              (8):709-717.                                    [44]  BERTHOLD  H  K,LAAKSONEN  R,LEHTIMÄKI  T,
          [32]  SHEN J,ARNETT D K,PARNELL L D,et al. The effect    et  al.  SREBP-1c  gene  polymorphism  is  associated  with
               of CYP7A1 polymorphisms on lipid responses to fenofi‐  increased inhibition of cholesterol-absorption in response
               brate[J]. J Cardiovasc Pharmacol,2012,59(3):254-259.  to ezetimibe treatment[J]. Exp Clin Endocrinol Diabetes,
          [33]  CARLSON L A. Nicotinic acid:the broad-spectrum lipid   2008,116(5):262-267.
               drug. A 50th anniversary review[J]. J Intern Med,2005,  [45]  KAWAMURA R,SAIKI H,TADA H,et al. Acute myocar‐
               258(2):94-114.                                      dial infarction in a 25-year-old woman with sitosterolemia
          [34]  ASLIBEKYAN  S,STRAKA  R  J,IRVIN  M  R,et  al.      [J]. J Clin Lipidol,2018,12(1):246-249.
               Pharmacogenomics  of  high-density  lipoprotein-cholesterol-   [46]  TADA H,NOHARA A,INAZU A,et al. Sitosterolemia,
               raising therapies[J]. Expert Rev Cardiovasc Ther,2013,11  hypercholesterolemia,and  coronary  artery  disease[J].  J
              (3):355-364.                                         Atheroscler Thromb,2018,25(9):783-789.
          [35]  TUTEJA S,WANG L,DUNBAR R L,et al. Genetic coding            (收稿日期:2022-10-20  修回日期:2023-03-24)
               variants  in  the  niacin  receptor,hydroxyl-carboxylic  acid                      (编辑:唐晓莲)
               receptor  2,and  response  to  niacin  therapy[J].  Pharmaco‐





          · 1152 ·    China Pharmacy  2023 Vol. 34  No. 9                              中国药房  2023年第34卷第9期
   133   134   135   136   137   138   139   140